Among the risk prediction tools, there was consensus that NHS Predict should be used to define high risk of recurrence in HR-positive/HER2-negative patients (95%, 18/19), and that the Residual Cancer Burden (RCB) Index should be used to define high risk of recurrence in TN patients (72%, 13/18). The gene discussed is ERBB2; the disease is cancer.